Adoption of AI Search by Healthcare Professionals (HCPs) and Changes in the Marketing Environment

With 81% of U.S. physicians using artificial intelligence (AI) tools for clinical practice and information acquisition, the pharmaceutical marketing environment is rapidly evolving. Previously, healthcare professionals (HCPs) directly searched academic papers or guidelines, but now they increasingly trust information summarized by AI assistants based on large language models (LLMs). As a result, pharmaceutical companies must consider new approaches to ensure their products are correctly cited in AI algorithms, going beyond simple information exposure. As AI gains control over the early stages of physicians' decision-making processes, the influence of traditional search advertising is rapidly declining.

Paradigm Shift from Share of Voice (SOV) to Share of Answer (SOA)

In this evolving landscape, the key marketing metric is shifting from the traditional Share of Voice (SOV) to Share of Answer (SOA). Share of Answer (SOA) refers to the proportion of times a company's brand is mentioned or cited when AI generates responses on specific diseases or treatments. Simply increasing ad impressions through budget allocation is no longer sufficient; if a brand is omitted from AI responses, it risks being completely excluded from clinical settings. Ultimately, the success or failure of pharmaceutical marketing hinges on how naturally and accurately a company's brand presence is embedded within the flow of AI-generated responses.

Generative Engine Optimization (GEO) and Structuring Reliable Clinical Data

Therefore, pharmaceutical companies must adopt Generative Engine Optimization (GEO) strategies to optimize data in a way that is easily learned and cited by large language models (LLMs). AI models prioritize information with consistent clinical relationships and high academic credibility, such as recognized Prescribing Information (PI) data. To achieve this, pharmaceutical companies should convert their product safety and efficacy data into machine-readable formats that AI can easily recognize. Without preemptively refining reliable data, AI responses may generate hallucinations or risk being outcompeted by rivals.

Strategic Importance of Data Engineering for Marketing Budget Efficiency

Ultimately, to maximize the efficiency of AI budgets in the global pharmaceutical marketing market, which is projected to reach approximately $33.8 billion by 2026, data infrastructure must be established first. PharmaForceIQ, led by Chief Operating Officer Stephen Onikoro, emphasizes the use of affinity data to analyze healthcare professionals' behavioral patterns rather than indiscriminate ad spending. Rather than focusing budgets solely on AI technology, building a hub of trustworthy content and data engineering capabilities will be the key to long-term growth.